Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

BackgroundSofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to...

ver descrição completa

Detalhes bibliográficos
Autores: Ruiz-Cobo, JC, Llaneras, J, Forns, X, Moya, AG, Amiel, IC, Arencibia, A, Diago, M, Garcia-Samaniego, J, Castellote, J, Llerena, S, Rodriguez-Seguel, E, Mateos, B, Rodriguez, M, Zabal, JMR, Fernandez, I, Calleja, JL, Morillas, RM, Montoliu, S, Andrade, RJ, Aranda, EB, Hernandez-Guerra, M, Mate, CJ, Gonzalez-Santiago, JM, de Cuenca, B, Bernal-Monterde, V, Delgado, M, Turnes, J, Lens, S, Buti, M
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p18135
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18135
http://ddd.uab.cat/record/293056
Access Level:acceso abierto
id ES_7e045c26586df8a4c898617f14acd043
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p18135
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirRuiz-Cobo, JCLlaneras, JForns, XMoya, AGAmiel, ICArencibia, ADiago, MGarcia-Samaniego, JCastellote, JLlerena, SRodriguez-Seguel, EMateos, BRodriguez, MZabal, JMRFernandez, ICalleja, JLMorillas, RMMontoliu, SAndrade, RJAranda, EBHernandez-Guerra, MMate, CJGonzalez-Santiago, JMde Cuenca, BBernal-Monterde, VDelgado, MTurnes, JLens, SButi, MBackgroundSofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).MethodsRetrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX +/- ribavirin for 12 weeks between December 2017 and December 2022.ResultsIn total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR.ConclusionSOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is an effective rescue therapy for patients with chronic hepatitis C infection who have failed SOF/VEL and glecaprevir/pibrentasvir (GLE/PIB), achieving sustained virological response (SVR) in 89% of patients who completed treatment. There is a non-significant trend towards lower SVR rates in patients with GT3 HCV infection, cirrhosis and prior therapy with SOF/VEL.imageWILEY2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18135http://ddd.uab.cat/record/293056ALIMENTARY PHARMACOLOGY & THERAPEUTICSISSN: 02692813ISSNe: 13652036reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p181352026-06-14T12:41:47Z
dc.title.none.fl_str_mv Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
title Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
spellingShingle Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Ruiz-Cobo, JC
title_short Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
title_full Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
title_fullStr Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
title_full_unstemmed Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
title_sort Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
dc.creator.none.fl_str_mv Ruiz-Cobo, JC
Llaneras, J
Forns, X
Moya, AG
Amiel, IC
Arencibia, A
Diago, M
Garcia-Samaniego, J
Castellote, J
Llerena, S
Rodriguez-Seguel, E
Mateos, B
Rodriguez, M
Zabal, JMR
Fernandez, I
Calleja, JL
Morillas, RM
Montoliu, S
Andrade, RJ
Aranda, EB
Hernandez-Guerra, M
Mate, CJ
Gonzalez-Santiago, JM
de Cuenca, B
Bernal-Monterde, V
Delgado, M
Turnes, J
Lens, S
Buti, M
author Ruiz-Cobo, JC
author_facet Ruiz-Cobo, JC
Llaneras, J
Forns, X
Moya, AG
Amiel, IC
Arencibia, A
Diago, M
Garcia-Samaniego, J
Castellote, J
Llerena, S
Rodriguez-Seguel, E
Mateos, B
Rodriguez, M
Zabal, JMR
Fernandez, I
Calleja, JL
Morillas, RM
Montoliu, S
Andrade, RJ
Aranda, EB
Hernandez-Guerra, M
Mate, CJ
Gonzalez-Santiago, JM
de Cuenca, B
Bernal-Monterde, V
Delgado, M
Turnes, J
Lens, S
Buti, M
author_role author
author2 Llaneras, J
Forns, X
Moya, AG
Amiel, IC
Arencibia, A
Diago, M
Garcia-Samaniego, J
Castellote, J
Llerena, S
Rodriguez-Seguel, E
Mateos, B
Rodriguez, M
Zabal, JMR
Fernandez, I
Calleja, JL
Morillas, RM
Montoliu, S
Andrade, RJ
Aranda, EB
Hernandez-Guerra, M
Mate, CJ
Gonzalez-Santiago, JM
de Cuenca, B
Bernal-Monterde, V
Delgado, M
Turnes, J
Lens, S
Buti, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
description BackgroundSofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).MethodsRetrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX +/- ribavirin for 12 weeks between December 2017 and December 2022.ResultsIn total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR.ConclusionSOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is an effective rescue therapy for patients with chronic hepatitis C infection who have failed SOF/VEL and glecaprevir/pibrentasvir (GLE/PIB), achieving sustained virological response (SVR) in 89% of patients who completed treatment. There is a non-significant trend towards lower SVR rates in patients with GT3 HCV infection, cirrhosis and prior therapy with SOF/VEL.image
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18135
http://ddd.uab.cat/record/293056
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18135
http://ddd.uab.cat/record/293056
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN: 02692813
ISSNe: 13652036
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411706254393344
score 15,812429

Registos relacionados